While we have tried to minimize this variability by standardizing age, disease status and linked specimens, it would be helpful to expand this study to examine defined cohorts of moyamoya (RNF213, Down syndrome, post-radiation, etc.)and determine if there are unique biomarker signatures across populations. Here, RNF213 is linked to Down syndrome.